Employing PD-L1 as the target moiety for RevCAR T-cells might be beneficial by additionally providing a positive feedback loop that could result in increased tumor cell killing over time, such as has already been described in other PD-L1 CARs31. The gene discussed is CD274; the disease is neoplasm.